From December 14 to 18, a delegation led by Lei Haichao, Director of China's National Health Commission, visited Japan to attend the 17th Tripartite Health Ministers’ Meeting and engage in a series of official activities.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for colorectal cancer.

OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC).

The Davos Alzheimer's Collaborative (DAC) announced on Wednesday that it is partnering with Janssen Research & Development and Danaher subsidiary Beckman Coulter Diagnostics to validate blood-based biomarkers for Alzheimer's disease.

China welcomes foreign friends to add China to their travel bucket list, and experience China's time-honored history by visiting heritage sites such as the Great Wall, feast their eyes on natural wonders such as the glinting West Lake, discover application of cutting-edge technologies, and feel the spirit of humanity embodied in winter dining delights, Lin Jian, spokesperson from China's Foreign Ministry told a press conference on Tuesday, following the latest visa-free policy update released by China's National Immigration Administration (NIA) on Tuesday morning.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in January 2025.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings.

Gastroenteritis is a common disease in infants and young children. The treatment of mild cases is based on the prevention and correction of dehydration, electrolyte disturbance, and acid-base imbalance, while anti-infective treatment should be considered for infants and young children with gastroenteritis that has obvious toxic symptoms and cannot be completely explained by dehydration.

North China's Tianjin Municipality issued a license for medical services on Monday to a wholly foreign-owned, third-grade general hospital, the first of its kind in the country.

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare & Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the ‘gapfill’ pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing for PrecisionCHD and Epi+Gen CHD based on actual cost data from Cardio Diagnostics. The Medicare contractors will report to CMS preliminary gapfill pricing for calendar year 2025 by April 1, 2025.